Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CDK4 | P11802 | 10/20 | 0.51 |
| ▸ | CDK2 | P24941 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5257349 | 0.98 | HIF1A (0.68) | HIF1AHTTALDH1A1HPGDCDK4 | |
| Hydrochloric Acid SCHEMBL5396629 | 0.98 | HIF1A (0.68) | HIF1AHTTALDH1A1HPGDCDK4 | |
| SCHEMBL22639742 | 0.84 | CDK4 (0.67) | HIF1AHTTALDH1A1HPGDCDK4 | |
| SCHEMBL19405224 | 0.84 | CDK4 (0.67) | HIF1AHTTALDH1A1HPGDCDK4 | |
| SCHEMBL3575066 | 0.83 | POLB (0.57) | HIF1AHTTALDH1A1POLBTDP1 | |
| SCHEMBL7934862 | 0.83 | MAPT (0.55) | HTTALDH1A1POLBSMN1; SMN2TDP1 | |
| SCHEMBL6223039 | 0.83 | MAPK1 (0.66) | HIF1AHTTALDH1A1HPGDCDK4 | |
| SCHEMBL258823 | 0.82 | HIF1A (0.75) | HIF1AHTTALDH1A1HPGDCDK4 | |
| SCHEMBL188859 | 0.81 | TDP1 (0.53) | HIF1AHTTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6049252 | 0.80 | TDP1 (0.55) | ALDH1A1POLBSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273154-B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | PROGENRA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2018160944-A1 | AZOLE COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE USP7 INHIBITORS | PROGENRA, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-7642270-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-05 | — | — | US | disclosed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7563781-B2 | Triazolopyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-21 | — | — | US | disclosed |
| US-6670368-B1 | Anti-cell-proliferation (such as anti-cancer); inhibitors ofcell cycle kinases, particularly CDK2, CDK4, and CDK6; 4-(4-(2- hydroxy-3- (N,N-dimethylamino)propoxy)anilino)-2-(2,5-dimethylphenoxy) pyrimidine; | ASTRAZENECA AB (SE) | 2003-12-30 | — | — | US | disclosed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| WO-2003051886-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2002066480-A2 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| EP-1214318-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1169307-A1 | PYRIMIDINE COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | AstraZeneca AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| EP-1107957-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000059892-A1 | PYRIMIDINE COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | ASTRAZENECA AB (SE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000012485-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273154-B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | USP7, USP1, USP2 | HIF1A 2497/4885HTT 3722/4885ALDH1A1 2210/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | HIF1A 1243/4885HTT 4847/4885ALDH1A1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.